# ACTIV-3: Therapeutics for Inpatients With COVID-19

> **NCT04501978** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 2753 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** LY3819253
- **DRUG:** Placebo
- **BIOLOGICAL:** Remdesivir
- **BIOLOGICAL:** VIR-7831
- **BIOLOGICAL:** BRII-196/BRII-198
- **BIOLOGICAL:** AZD7442
- **DRUG:** MP0420
- **DRUG:** PF-07304814

## Key facts

- **NCT ID:** NCT04501978
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2022-04-06
- **Final completion:** 2023-07-14
- **Target enrollment:** 2753 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501978, "ACTIV-3: Therapeutics for Inpatients With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04501978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*